Reducing the reliance on oral corticosteroids in patients with severe asthma is a critical mission, given the adverse effects, healthcare costs, and impact on quality of life associated with these medications.
A study published in Allergy emphasized the urgent necessity for clear tapering guidelines and collaborative patient-provider strategies to address the significant adverse effects and increased healthcare costs linked to oral corticosteroids in managing severe asthma for over 70 years.
Although a recent move by major inhaler manufacturers to cap out-of-pocket costs at $35 monthly is a step towards accessibility, challenges remain, particularly for individuals with public insurance. The review of benefits and burdens associated with oral corticosteroids in severe asthma underscores the need for strategies to reduce reliance on these medications, from both patient and provider perspectives.
- Unveiling the Impact of Oral Corticosteroids:
- Systemic corticosteroids administered in the emergency department for acute asthma exacerbations play a vital role in reducing hospitalization risk, particularly in severe cases.
- Oral corticosteroids have been shown to significantly prevent asthma worsening post-exacerbation and offer a cost-effective treatment.
- Despite being dubbed a “necessary evil,” patients often regard oral corticosteroids as an effective safety net for severe asthma, highlighting their crucial role in managing the condition.
- Burdens of Oral Corticosteroids:
- Frequent short courses and long-term use of oral corticosteroids pose substantial burdens for patients and healthcare systems, especially in the face of new asthma therapies.
- The well-established adverse effects of oral corticosteroids, coupled with the risk of serious comorbidities and increased healthcare utilization, underscore the need for alternative treatment options.
- The Role of Biologics in Reducing Oral Corticosteroid Dependence:
- Biologics present a significant advancement in treating severe asthma, particularly for patients with type 2 inflammation.
- Omalizumab and IL-5/IL-5 receptor biologics have demonstrated substantial reductions in oral corticosteroid doses, with dupilumab emerging as a game-changer in enabling patients to discontinue oral corticosteroids entirely.
- Addressing Healthcare System Challenges:
- Challenges such as the lack of centralized oral corticosteroid monitoring and limited access to biologics necessitate a shift towards more informed prescribing practices and increased awareness of oral corticosteroid stewardship guidelines.
- Patient-Related Barriers and Solutions:
- Patient anxiety regarding symptom return or adverse effects from new treatments, coupled with the over-reliance on oral corticosteroids, calls for enhanced education and alternative treatment options to facilitate successful tapering.
In the pursuit of reducing oral corticosteroid dependence in severe asthma, the integration of biologics and the implementation of tailored tapering strategies are paramount. By balancing the benefits of oral corticosteroids with the burdens they impose, healthcare providers can navigate towards safer and more effective care pathways for patients with severe asthma.
Takeaways:
– Biologics offer a promising avenue for reducing oral corticosteroid dependence in severe asthma, with the potential to significantly improve patient outcomes.
– Clear tapering guidelines and collaborative patient-provider strategies are essential in addressing the adverse effects and healthcare costs associated with oral corticosteroids.
– Enhanced education and alternative treatment options can help overcome patient-related barriers to reducing oral corticosteroid dependence.
– Healthcare systems must prioritize centralized monitoring of oral corticosteroid use and improve access to biologics to optimize asthma management.
– The journey towards safer care in severe asthma involves a delicate balance between maximizing the benefits of oral corticosteroids and minimizing the burdens they place on patients and healthcare systems.
Tags: immunotherapy, clinical trials
Read more on ajmc.com
